SEC Company Response from Scopus BioPharma Inc. (SCPS) (CIK 0001772028) — Dec 3, 2020
Scopus BioPharma Inc. (SCPS) (CIK 0001772028)
Date: Dec. 3, 2020 · CIK: 0001772028 · Accession: 0001104659-20-132035
AI Filing Summary & Sentiment
File numbers found in text: 024-11228
Letter
Mark J. Wishner
Tel: 703-749-1352
Wishnerm@gtlaw.com
December 3, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Laura Crotty
Celeste Murphy
Re: Scopus BioPharma Inc.
Post-Effective Amendment to Form 1-A
Response dated December 1, 2020
File No. 024-11228
Ladies:
On behalf of Scopus BioPharma Inc. (the “Company”), we submit this letter in response to comments from the staff (the “Staff”) of the United States Securities and Exchange Commission (the “Commission”) received by letter, dated December 2, 2020, relating to the comment letter response the Company filed on December 1, 2020 regarding the Post-Effective Amendment to Form 1-A, File No. 024-11228.
Please note that for the Staff’s convenience, we have recited each of the Staff’s comments and have provided the Company’s response to each comment immediately thereafter.
Comment
Management's Discussion and Analysis of Financial Condition and Results of Operations Six Months Ended June 30, 2020 versus Six Months Ended June 30, 2019, page 44
1. We note your response to our prior comment. Please further revise your proposed disclosure to provide detail regarding the $383,195 paid to the company's president in the six months ended June 30, 2020 (i.e., salary, award, etc.). In this regard we note your disclosure on page 79 that the employment agreement for Mr. Sanghrajka provides for the payment of an annual base salary of $300,000 for "the remainder of 2020 and increases to $360,000 and $414,000 for the years ended December 31, 2021 and 2022" and that a guaranteed bonus will be paid at year end; however, no detail is given regarding payments made in the first six months of the year.
Response
When the Company amends its offering statement prior to its request for qualification, it will further supplement its proposed disclosure regarding the compensation payable to its president with the insertion of the following at the end of the paragraph in which the amount attributable to the president’s compensation is discussed.
Of the total general and administrative expenses attributable to our president, $166,994 represents half of his annual base compensation for 2020, including $16,994 of payroll taxes and fees, all of which have been paid in cash, $150,000 represents an accrual for his guaranteed bonus for 2020, and $66,201 is the value of the compensatory charge associated with the prior grant of stock options to our president.
If additional disclosure is required, please let us know.
We will also make certain to advise the underwriter to have FINRA advise the Commission that it has no objection to the compensation arrangements.
Sincerely,
/s/ Mark J. Wishner
Show Raw Text
CORRESP
1
filename1.htm
Mark J. Wishner
Tel: 703-749-1352
Wishnerm@gtlaw.com
December 3, 2020
United States Securities and
Exchange Commission
Division of Corporation
Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention:
Laura Crotty
Celeste Murphy
Re:
Scopus BioPharma Inc.
Post-Effective Amendment to Form 1-A
Response dated December 1, 2020
File No. 024-11228
Ladies:
On behalf of
Scopus BioPharma Inc. (the “Company”), we submit this letter in response to comments from the staff (the
“Staff”) of the United States Securities and Exchange Commission (the “Commission”) received by
letter, dated December 2, 2020, relating to the comment letter response the Company filed on December 1, 2020 regarding the
Post-Effective Amendment to Form 1-A, File No. 024-11228.
Please
note that for the Staff’s convenience, we have recited each of the Staff’s comments and have provided the Company’s
response to each comment immediately thereafter.
Comment
Management's Discussion
and Analysis of Financial Condition and Results of Operations Six Months Ended June 30, 2020 versus Six Months Ended June 30, 2019,
page 44
1. We note your response to our prior comment. Please further revise your proposed disclosure to provide detail regarding the
$383,195 paid to the company's president in the six months ended June 30, 2020 (i.e., salary, award, etc.). In this regard we note
your disclosure on page 79 that the employment agreement for Mr. Sanghrajka provides for the payment of an annual base salary of
$300,000 for "the remainder of 2020 and increases to $360,000 and $414,000 for the years ended December 31, 2021 and 2022"
and that a guaranteed bonus will be paid at year end; however, no detail is given regarding payments made in the first six months
of the year.
Response
When the Company amends
its offering statement prior to its request for qualification, it will further supplement its proposed disclosure regarding the
compensation payable to its president with the insertion of the following at the end of the paragraph in which the amount attributable
to the president’s compensation is discussed.
Of the total general and administrative
expenses attributable to our president, $166,994 represents half of his annual base compensation for 2020, including $16,994 of
payroll taxes and fees, all of which have been paid in cash, $150,000 represents an accrual for his guaranteed bonus for 2020,
and $66,201 is the value of the compensatory charge associated with the prior grant of stock options to our president.
If additional disclosure is
required, please let us know.
We will
also make certain to advise the underwriter to have FINRA advise the Commission that it has no objection to the compensation arrangements.
Sincerely,
/s/ Mark J. Wishner
cc: Robert J. Gibson